

Porzio's Bankruptcy and Financial Restructuring Team Chosen to Represent Unsecured Creditors' Committee for Immune Pharmaceutical

March 13, 2019

By: [Robert Schechter](#), [Kelly Curtin](#)

Amongst strong competition, Porzio was selected to represent the Official Committee of Unsecured Creditors (the "Committee") in the Chapter 11 proceedings for the following debtor entities: Immune Pharmaceuticals, Inc.; Immune Pharmaceuticals, Ltd.; Cytovia, Inc.; Immune Oncology Pharmaceuticals, Inc.; Maxim Pharmaceuticals, Inc.; and Immune Pharmaceuticals USA Corp. (collectively, the "Debtors"). The Debtors are a clinical stage biopharmaceutical company specializing in the development of novel targeted therapeutic agents in the fields of inflammation, dermatology, and oncology. The Debtors' Chapter 11 cases are pending in the United States Bankruptcy Court for the District of New Jersey. The Porzio attorneys representing the Committee are [John Mairo](#), [Robert Schechter](#), and [Kelly Curtin](#).